Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Testosterone treatment in multiple sclerosis: a pilot study.

Nancy L Sicotte1, Barbara S Giesser, Vinita Tandon

  • 1Division of Brain Mapping, Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Archives of Neurology
|May 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pretending to Be Normal: Cross-Cultural Adaptation and Validation of the Camouflaging Autistic Traits Questionnaire in Iran.

Autism : the international journal of research and practice·2026
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

Childhood trauma as a mediator between autistic traits and depression: Evidence from the ALSPAC birth cohort.

Psychological medicine·2026
Same author

Corrigendum to Validation of the Camouflaging Autistic Traits Questionnaire Short Form (CATQ-SF). Comprehensive Psychiatry 135 (2024) Nov:135:152525.

Comprehensive psychiatry·2026
Same author

Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

A Multicomponent Approach to Screening for Dementia in Older Hospitalized Patients.

Journal of the American Geriatrics Society·2026
Same journal

Incorrect Table Entries and Word.

Archives of neurology·2016
Same journal

IDEAL for CCSVI Research-Reply.

Archives of neurology·2013
Same journal

Atlas of Inherited Metabolic Diseases, 3rd ed.

Archives of neurology·2013
Same journal

Error in byline: in heterogeneity of coenzyme q10 deficiency: patient study and literature review.

Archives of neurology·2013
Same journal

This month in archives of neurology.

Archives of neurology·2013
Same journal

About this journal.

Archives of neurology·2013
See all related articles

Testosterone supplementation improved cognitive function and reduced brain atrophy in men with multiple sclerosis (MS). This study suggests testosterone may offer neuroprotective benefits for MS patients.

Area of Science:

  • Neuroimmunology
  • Endocrinology
  • Neurology

Background:

  • Men exhibit lower susceptibility to autoimmune diseases like multiple sclerosis (MS) compared to women.
  • Sex hormones, including testosterone, and sex chromosomes are hypothesized to influence this difference.
  • Testosterone administration has shown promise in animal models of MS, but its effects in human patients remain uninvestigated.

Purpose of the Study:

  • To investigate the impact of testosterone supplementation on men diagnosed with relapsing-remitting multiple sclerosis (RRMS).
  • To evaluate the safety and tolerability of testosterone treatment in this population.

Main Methods:

  • A crossover study design was employed with 10 male RRMS patients serving as their own controls.
  • Participants underwent a 6-month pretreatment phase followed by 12 months of daily testosterone gel (10g containing 100mg testosterone).

Related Experiment Videos

  • Clinical assessments included the Multiple Sclerosis Functional Composite and 7/24 Spatial Recall Test; MRI monitored enhancing lesions and brain volumes.

    • Main Results:

    • Testosterone treatment over one year led to significant improvements in cognitive performance (P = .008) and a reduction in brain atrophy rates (P <.001).
    • No significant changes were observed in the number or volume of gadolinium-enhancing lesions (P = .31 and P = .94, respectively).
    • A significant increase in lean body mass (muscle mass) was noted (P = .02).

    Conclusions:

    • Testosterone supplementation demonstrated safety and good tolerability in men with RRMS.
    • The findings suggest potential neuroprotective effects of testosterone treatment in this patient group.
    • Further research is warranted to explore testosterone's therapeutic role in male MS patients.